Daihan PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 6/6
Daihan PharmaceuticalLtd has a total shareholder equity of ₩268.3B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩313.4B and ₩45.0B respectively. Daihan PharmaceuticalLtd's EBIT is ₩37.2B making its interest coverage ratio -42.3. It has cash and short-term investments of ₩73.9B.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | -42.3x |
| Cash | ₩73.89b |
| Equity | ₩268.33b |
| Total liabilities | ₩45.02b |
| Total assets | ₩313.35b |
Recent financial health updates
Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly
Mar 02
Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?
Nov 27Recent updates
Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly
Mar 02Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Feb 09
Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?
Jan 19What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?
Dec 18Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?
Nov 27Financial Position Analysis
Short Term Liabilities: A023910's short term assets (₩132.5B) exceed its short term liabilities (₩38.3B).
Long Term Liabilities: A023910's short term assets (₩132.5B) exceed its long term liabilities (₩6.7B).
Debt to Equity History and Analysis
Debt Level: A023910 is debt free.
Reducing Debt: A023910 has no debt compared to 5 years ago when its debt to equity ratio was 18.6%.
Debt Coverage: A023910 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A023910 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 19:35 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Daihan Pharmaceutical Co.,Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jang-wook Park | Daishin Securities Co. Ltd. |
| Hong-Sik Jeong | LS Securities Co., Ltd. |